When SGLT2 med Farxiga scored a major cardiovascular outcomes win last month, AstraZeneca touted the drug’s trial results as a game changer for the market. Turns out the FDA likes those results, ...

AstraZeneca is still stinging after its SGLT2 diabetes drug Farxiga was waved off by the FDA in Type 1 disease. But here's something that could ease the pain: New outcomes data showing Farxiga cut ...

AstraZeneca has scored a major trial victory after its Farxiga (dapagliflozin) became the first drug in its class to show efficacy in heart failure, in patients with or without type-2 diabetes.

AstraZeneca has moved a step close to a chronic heart failure claim for its diabetes drug Farxiga after reporting positive results in a phase 3 trial. The phase 3 DAPA-HF trial has shown that SGLT2 ...

AstraZeneca’s Farxiga (dapagliflozin) has scored fast track designation (FTD) from the FDA in the US, continuing its upward trajectory in heart failure. Earlier this month, AZ revealed the results of ...

AstraZeneca’s diabetes drug Farxiga could face generic competition in the US, after the FDA gave tentative approval to a generic rival from India’s Glenmark, although it is unclear when the potential ...

Indication: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The FDA has approved Farxiga (dapagliflozin) to reduce the risk of cardiovascular ...

AstraZeneca AZN announced that the FDA granted label expansion to its blockbuster drug Farxiga (dapagliflozin) to treat pediatric patients aged 10 years and older with type-2 diabetes (T2D). Farxiga ...